Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) EPS (Weighted Average and Diluted) (2016 - 2023)

Historic EPS (Weighted Average and Diluted) for Ekso Bionics Holdings (EKSO) over the last 11 years, with Q1 2023 value amounting to -$0.33.

  • Ekso Bionics Holdings' EPS (Weighted Average and Diluted) rose 830.58% to -$0.33 in Q1 2023 from the same period last year, while for Mar 2023 it was -$1.22, marking a year-over-year decrease of 3515.34%. This contributed to the annual value of -$1.21 for FY2022, which is 3774.53% down from last year.
  • Per Ekso Bionics Holdings' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.33 for Q1 2023, which was up 830.58% from -$0.35 recorded in Q4 2022.
  • Over the past 5 years, Ekso Bionics Holdings' EPS (Weighted Average and Diluted) peaked at $0.04 during Q3 2019, and registered a low of -$1.88 during Q2 2020.
  • Over the past 5 years, Ekso Bionics Holdings' median EPS (Weighted Average and Diluted) value was -$0.33 (recorded in 2022), while the average stood at -$0.37.
  • As far as peak fluctuations go, Ekso Bionics Holdings' EPS (Weighted Average and Diluted) skyrocketed by 13636.36% in 2019, and later crashed by 160000.0% in 2021.
  • Over the past 5 years, Ekso Bionics Holdings' EPS (Weighted Average and Diluted) (Quarter) stood at $0.04 in 2019, then tumbled by 1154.93% to -$0.42 in 2020, then surged by 38.38% to -$0.26 in 2021, then tumbled by 33.59% to -$0.35 in 2022, then grew by 4.96% to -$0.33 in 2023.
  • Its EPS (Weighted Average and Diluted) was -$0.33 in Q1 2023, compared to -$0.35 in Q4 2022 and -$0.33 in Q3 2022.